id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-1428-0002,FDA,FDA-2013-N-1428,"Guidance for Industry Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Other,Guidance,2013-12-04T05:00:00Z,2013,12,2013-12-04T05:00:00Z,,2024-11-12T05:23:40Z,,1,0,09000064814a6674
FDA-2013-N-1428-0001,FDA,FDA-2013-N-1428,"Draft Guidance for Industry on Interim Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Availability",Notice,Notice of Availability,2013-12-04T05:00:00Z,2013,12,2013-12-04T05:00:00Z,2014-02-04T04:59:59Z,2019-07-17T12:21:27Z,2013-28960,0,0,09000064814a6172